Theravance merger closes, delisting begins as ampreloxetine upside shifts to CVR

Theravance was already transitioning into a lean commercial business centered on YUPELRI after the failed CYPRESS study led it to wind down ampreloxetine development and cut operating costs. The transaction now formally ends that standalone strategy. Zymeworks completed the merger on September 23, 2026, making Theravance a wholly owned subsidiary and converting existing shares into the merger consideration. 〔0〕 (Merger completion)

For shareholders, this is execution of an already-announced outcome—not a new operating catalyst. The acquisition had been agreed on June 28, 2026 and was expected to close in the second half of 2026, so the main change is removal of closing risk rather than a revision to the economic terms. The company has requested Nasdaq suspension and delisting, with the Form 25 process making the public-company exit effective after the statutory period. 〔1〕 (Nasdaq delisting)

The remaining upside is deliberately uncertain and operationally outsourced to Zymeworks. Each holder receives a CVR tied to potential future license proceeds, a first commercial-sale milestone, or royalties from ampreloxetine, but the agreement gives Zymeworks broad discretion over whether and how to develop or monetize the asset. 〔2〕 (CVR Agreement, Sections 1.1 and 2.4) Susannah Gray has been retained for 12 months to negotiate a possible license transaction, with up to $400,000 of outside-adviser costs funded by the company. 〔3〕 (Consultation Agreement)

Leadership and public-company infrastructure are being removed as part of the closing. The board and CEO Rick Winningham resigned in connection with the merger, with no stated disagreement, while the surviving entity adopts merger-sub constitutional documents. 〔4〕 (Change in control and executive resignations)

Bottom line: This filing completes the expected sale and shuts down Theravance as an independent listed company. The business story now rests mainly on YUPELRI under Zymeworks and on a speculative, separately defined chance that ampreloxetine can still be monetized through the CVR.